Ibnsina Pharma (ISPH) Revenue
Revenue
EGP 80.05B
Trailing 12 months (TTM)
As of 23 Jul 2026, 19:29 (Cairo time)
Revenue (also called sales or turnover) is the total income a company generates from its core business before any costs or expenses are deducted. For EGX-listed companies it is reported in the annual income statement in Egyptian pounds.
Revenue history
| Fiscal year | Revenue | YoY growth |
|---|---|---|
| 2025 | 76.6B | 37.17% |
| 2024 | 55.84B | 64.49% |
| 2023 | 33.95B | 52.48% |
| 2022 | 22.26B | 2.45% |
| 2021 | 21.73B | 16.35% |
| 2020 | 18.68B | 12.52% |
| 2019 | 16.6B | 24.59% |
| 2018 | 13.32B | 38.99% |
| 2017 | 9.59B | 33.03% |
| 2016 | 7.21B | 35.3% |
| 2015 | 5.33B | — |
All monetary figures in EGP. Source: Egyptian Exchange via TradingView; annual figures from company disclosures; updated weekly. Prices refresh every 15 minutes during EGX trading hours.